PELDESINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H11N5O
Molecular Weight	241.2486
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC2=C(NC=C2CC3=CN=CC=C3)C(=O)N1

InChI

InChIKey=DOHVAKFYAHLCJP-UHFFFAOYSA-N

InChI=1S/C12H11N5O/c13-12-16-9-8(4-7-2-1-3-14-5-7)6-15-10(9)11(18)17-12/h1-3,5-6,15H,4H2,(H3,13,16,17,18)

HIDE SMILES / InChI

Molecular Formula	C12H11N5O
Molecular Weight	241.2486
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11369904 | https://clinicaltrials.gov/ct2/show/NCT00002237 | https://www.ncbi.nlm.nih.gov/pubmed/10828318

Peldesine (also known as BCX-34) was developed as a purine nucleoside phosphorylase (PNP) inhibitor. It is known PNP inhibitors may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis, and Crohn s disease and T-cell cancers. Peldesine has undergone phase I trials for the treatment of human Immunodeficiency virus (HIV) infections. In addition, this drug participated in phase III clinical trial as a topical therapy for cutaneous T-cell lymphoma. This drug was also studied as a potential therapy for psoriasis, multiple sclerosis; rheumatoid arthritis; transplant rejection. However, all these indications were discontinued because of the lack of significant effects over placebo.

Approval Year

PubMed

Title	Date	PubMed
A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.	2001 Jun	11369904
Evaluation of creams and ointments as suitable formulations for peldesine.	2001 May 21	11337167
Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes.	2003 Dec	14680377
Case study: institutional review board (IRB) did not know about subject problem until after study.	2006 May	16832916

Patents

Sample Use Guides

In Vivo Use Guide

peldesine (BCX-34) in a 1% dermal cream formulation. BCX-34 dermal cream 1% or the vehicle cream (as a placebo control) was applied twice daily to the entire skin surface for up to 24 weeks.

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Sat Dec 16 06:14:35 GMT 2023` Edited by `admin` on `Sat Dec 16 06:14:35 GMT 2023`
Record UNII	7B646RJ70F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PELDESINE

Official Name

English

4H-PYRROLO(3,2-D)PYRIMIDIN-4-ONE, 2-AMINO-3,5-DIHYDRO-7-(3-PYRIDINYLMETHYL)-

Systematic Name

English

Peldesine [WHO-DD]

Common Name

English

2-Amino-3,5-dihydro-7-(3-pyridylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one

Systematic Name

English

BCX-34

Code

English

PELDESINE [USAN]

Common Name

English

peldesine [INN]

Common Name

English

PELDESINE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2151